ARF-nonspecified: A Potential Drug Target (P10836)

Target Name: ADP-Ribosylation Factor

NCBI ID: P10836

ADP-Ribosylation Factor

Other Name(s): ARF

ARF-nonspecified: A Potential Drug Target

Unlocking the Potential of ADP-Ribosylation Factor (nonspecified subtype) (ARF) as a Drug Target: A Comprehensive Review

Abstract:

Adp-ribosylated factor (ARF) is a protein that plays a crucial role in various cellular processes, including metabolism, energy homeostasis, and stress response. The nonspecific subtype of ARF (ARF-nonspecified), has been identified as a potential drug target in the context of various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. In this review, we will discuss the current understanding of ARF-nonspecified and its potential as a drug target, highlighting recent research developments and future directions for research in this field.

Introduction:

Adp-ribosylated factor (ARF) is a protein that belongs to the superfamily of nucleotide-binding proteins (NBP), which are known to regulate various cellular processes, including metabolism, energy homeostasis, and stress response. ARF is composed of two structural domains : a nucleotide-binding domain (NBD) and a catalytic domain (CBD). The NBD is responsible for binding to specific nucleotides, while the CBD is involved in the catalytic activity of the protein.

ARF has been identified in various cellular contexts, including the cytosol of eukaryotic cells, and it is involved in various cellular processes, including protein synthesis, DNA replication, and stress response. ARF has also been implicated in various diseases, including cancer, neurodegenerative disorders , and metabolic diseases.

The nonspecific subtype of ARF (ARF-nonspecified) has been identified as a potential drug target in the context of various diseases. This subtype of ARF is different from other ARFs, such as ARF-1, which is involved in cell survival and cytoskeletal organization , and ARF-2, which is involved in protein synthesis and metabolism.

Potential Druggable Sites:

The ARF-nonspecified subtype has several potential druggable sites, including:

1.Conserved 尾-sheet-rich region: This region is involved in various cellular processes and has been implicated in various diseases, including cancer. Therefore, targeting this region may be a promising strategy for drug development.

2. GTP-binding site: This site is involved in protein-protein interactions and has been implicated in various diseases, including cancer. Therefore, targeting this site may be a promising strategy for drug development.

3. Phosphorylation sites: This site is involved in protein-protein interactions and has been implicated in various diseases, including cancer. Therefore, targeting this site may be a promising strategy for drug development.

Drugs Targeting ARF-nonspecified:

Several drugs have been developed and are currently in use that target ARF-nonspecified. These drugs include:

1. NEDD8: NEDD8 is an enzyme that is involved in the DNA damage response. It has been shown to be involved in various diseases, including cancer. Therefore, drugs that target NEDD8 may be effective in treating cancer associated with ARF-nonspecified.

2. ARF-1: ARF-1 is a protein that is involved in cell survival and cytoskeletal organization. It has been shown to be involved in various diseases, including cancer. Therefore, drugs that target ARF-1 may be effective in treating cancer associated with ARF-nonspecified.

3. ARF-2: ARF-2 is a protein that is involved in protein synthesis and metabolism. It has been shown to be involved in various diseases, including cancer. Therefore, drugs that target ARF-2 may be effective in treating cancer associated with ARF-nonspecified.

4.

Protein Name: ADP-Ribosylation Factor (nonspecified Subtype)

The "ADP-Ribosylation Factor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADP-Ribosylation Factor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets